214 related articles for article (PubMed ID: 19998318)
1. Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Filion KB; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):343-50. PubMed ID: 19998318
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
[TBL] [Abstract][Full Text] [Related]
3. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
4. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
Stockl KM; Le L; Zhang S; Harada AS
Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
[TBL] [Abstract][Full Text] [Related]
5. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
[TBL] [Abstract][Full Text] [Related]
6. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus.
Filion KB; Joseph L; Boivin JF; Suissa S; Brophy JM
Pharmacoepidemiol Drug Saf; 2011 Aug; 20(8):785-96. PubMed ID: 21671441
[TBL] [Abstract][Full Text] [Related]
8. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
9. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
10. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
11. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Pinelli NR; Cha R; Brown MB; Jaber LA
Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
[TBL] [Abstract][Full Text] [Related]
12. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents.
Koro C; Barrett S; Qizilbash N
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):485-92. PubMed ID: 17192841
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
Lipscombe LL; Gomes T; Lévesque LE; Hux JE; Juurlink DN; Alter DA
JAMA; 2007 Dec; 298(22):2634-43. PubMed ID: 18073359
[TBL] [Abstract][Full Text] [Related]
14. Metformin and the incidence of prostate cancer in patients with type 2 diabetes.
Azoulay L; Dell'Aniello S; Gagnon B; Pollak M; Suissa S
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):337-44. PubMed ID: 21148757
[TBL] [Abstract][Full Text] [Related]
15. Use of thiazolidinediones and fracture risk.
Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
[TBL] [Abstract][Full Text] [Related]
16. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
Koro CE; Sowell MO; Stender M; Qizilbash N
Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
[TBL] [Abstract][Full Text] [Related]
17. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.
Lin HC; Hsu YT; Kachingwe BH; Hsu CY; Uang YS; Wang LH
J Clin Pharm Ther; 2014 Aug; 39(4):354-60. PubMed ID: 24661226
[TBL] [Abstract][Full Text] [Related]
18. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
[TBL] [Abstract][Full Text] [Related]
19. Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control study.
Chang SS; Hu HY
BMC Cancer; 2013 Sep; 13():420. PubMed ID: 24041200
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
